228 related articles for article (PubMed ID: 24726032)
21. Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline.
Al-Hameed F; Al-Dorzi HM; AlMomen A; Algahtani F; AlZahrani H; AlSaleh K; AlSheef M; Owaidah T; Alhazzani W; Neumann I; Wiercioch W; Brozek J; Schünemann H; Akl EA
Ann Saudi Med; 2015; 35(2):95-106. PubMed ID: 26336014
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
23. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
24. Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II.
Spirk D; Ugi J; Korte W; Husmann M; Hayoz D; Baldi T; Frauchiger B; Banyai M; Aujesky D; Baumgartner I; Kucher N
Thromb Haemost; 2011 Jun; 105(6):962-7. PubMed ID: 21475778
[TBL] [Abstract][Full Text] [Related]
25. Parenteral anticoagulation in ambulatory patients with cancer.
Akl EA; Kahale LA; Ballout RA; Barba M; Yosuico VE; van Doormaal FF; Middeldorp S; Bryant A; Schünemann H
Cochrane Database Syst Rev; 2014 Dec; (12):CD006652. PubMed ID: 25491949
[TBL] [Abstract][Full Text] [Related]
26. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients.
Levine M
Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():9-11. PubMed ID: 14730472
[TBL] [Abstract][Full Text] [Related]
27. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
Li A; Garcia DA; Lyman GH; Carrier M
Thromb Res; 2019 Jan; 173():158-163. PubMed ID: 29506866
[TBL] [Abstract][Full Text] [Related]
28. Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study).
Tullett J; Murray E; Nichols L; Holder R; Lester W; Rose P; Hobbs FD; Fitzmaurice D
BMC Cardiovasc Disord; 2013 Mar; 13():16. PubMed ID: 23497371
[TBL] [Abstract][Full Text] [Related]
29. Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study.
Gould DW; Doidge J; Sadique MZ; Borthwick M; Hatch R; Caskey FJ; Forni L; Lawrence RF; MacEwen C; Ostermann M; Mouncey PR; Harrison DA; Rowan KM; Young JD; Watkinson PJ
Health Technol Assess; 2022 Feb; 26(13):1-58. PubMed ID: 35212260
[TBL] [Abstract][Full Text] [Related]
30. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.
Lindmarker P; Holmström M
J Intern Med; 1996 Dec; 240(6):395-401. PubMed ID: 9010387
[TBL] [Abstract][Full Text] [Related]
31. [Bridging: Perioperative management of chronic anticoagulation or antiplatelet therapy].
Nowak-Göttl U; Langer F; Limperger V; Mesters R; Trappe RU
Dtsch Med Wochenschr; 2014 Jun; 139(24):1301-6. PubMed ID: 24892468
[TBL] [Abstract][Full Text] [Related]
32. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
33. Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
van Rein N; Biedermann JS; van der Meer FJM; Cannegieter SC; Wiersma N; Vermaas HW; Reitsma PH; Kruip MJHA; Lijfering WM
J Thromb Haemost; 2017 Jul; 15(7):1386-1391. PubMed ID: 28440008
[TBL] [Abstract][Full Text] [Related]
34. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
35. Anticoagulation for perioperative thromboprophylaxis in people with cancer.
Matar CF; Kahale LA; Hakoum MB; Tsolakian IG; Etxeandia-Ikobaltzeta I; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009447. PubMed ID: 29993117
[TBL] [Abstract][Full Text] [Related]
36. Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT.
Shalhoub J; Lawton R; Hudson J; Baker C; Bradbury A; Dhillon K; Everington T; Gohel MS; Hamady Z; Hunt BJ; Stansby G; Warwick D; Norrie J; Davies AH
Health Technol Assess; 2020 Dec; 24(69):1-80. PubMed ID: 33275096
[TBL] [Abstract][Full Text] [Related]
37. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
38. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.
Phelps MK; Wiczer TE; Erdeljac HP; Van Deusen KR; Porter K; Philips G; Wang TF
J Oncol Pharm Pract; 2019 Jun; 25(4):793-800. PubMed ID: 29460705
[TBL] [Abstract][Full Text] [Related]
39. Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial.
Hutchinson A; Rees S; Young A; Maraveyas A; Date K; Johnson MJ
Palliat Med; 2019 May; 33(5):510-517. PubMed ID: 30488789
[TBL] [Abstract][Full Text] [Related]
40. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects.
Hull RD; Pineo GF; Raskob GE
Haemostasis; 1998; 28 Suppl 3():8-16. PubMed ID: 10069757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
